A review of the non-Alzheimer dementias

Journal of Clinical Psychiatry

Volumn 67, Issue 12, 2006, Pages 1985-2001

  Boeve, Bradley F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CREATINE; DONEPEZIL; FLUDROCORTISONE; FLUPIRTINE; MELATONIN; MEMANTINE; MEPACRINE; MIDODRINE; MINOCYCLINE; PAROXETINE; PLACEBO; RIVASTIGMINE; TRAZODONE; VALPROIC ACID;

APHASIA; BRAIN ATROPHY; BRAIN DEGENERATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOBASAL DEGENERATION; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FRONTOTEMPORAL DEMENTIA; GAIT; HEALTH EDUCATION; HUMAN; HUNTINGTON CHOREA; LEWY BODY; NEUROPATHOLOGY; NONHUMAN; OCCUPATIONAL THERAPY; PARKINSON DISEASE; PARKINSONISM; PHYSIOTHERAPY; PRION DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; TAUOPATHY;

EID: 33845975269     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1221     Document Type: Review

References (98)

1. Liefer B. Early diagnosis of Alzheimer's disease: clinical and economic benefits. J Am Geriatr Soc 2003;51:S281-S288
2. Boeve B. Diagnosis and management of the non-Alzheimer dementias. In: Noseworthy JW, ed. Neurologic Therapeutics. London, England: Martin Dunitz; 2003:2826-2854
3. Hou C, Carlin D, Miller B. Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates. Can J Psychiatry 2004;49:164-171
4. Pick A. Ueber die Bexiehungen der senilen Hirnatrophie zur Aphasie. Pragur Medicinische Wochenschrift 1892;17:165-167
5. Dickson DW. Pick's disease: a modern approach. Brain Pathol 1998;8:339-354
6. Rebeiz J, Kolodny E, Richardson E. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc 1967;92:23-26
7. Boeve B, Lang A, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003;54:S15-S19
8. Boeve BF, Maraganore DM, Parisi JE, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999;53:795-800
9. Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999;53:1969-1974
10. Dickson D, Bergeron C, Chin S, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002;61:935-946
11. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333-359
12. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996;47:1-9
13. Josephs K, Boeve B, Duffy J, et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 2005;11:283-296
14. Rippon G, Boeve B, Parisi J, et al. Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology. Neurocase 2005;11:204-211
15. Hauw J-J, Daniel S, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steel-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-2019
16. Josephs K, Dickson D. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 2003;18:1018-1026
17. Foster N, Wilhelmsen K, Sima A, et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997;41:706-715
18. van Swieten J, Rosso S, van Herpen E, et al. Phenotypic variation in frontotemporal dementia and parkinsonism linked to chromosome 17. Dement Geriatr Cogn Disord 2004;17:261-264
19. Reed L, Wszolek Z, Hutton M. Phenotypic correlations in FTDP-17. Neurobiol Aging 2001;22:89-107
20. Boeve B, Tremont-Lukats I, Waclawik A, et al. Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. Brain 2005;128:752-772
21. Ghetti B, Hutton M, Wszolek Z. Frontotemporal dementia and parkinsonism linked to chromosome 17 associated with tau gene mutations (FTDP-17T). In: Dickson D, ed. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel, Switzerland: ISN Neuropath Press; 2003:86-102
22. Okazaki H, Lipkin L, Aronson S. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961;20:237-244
23. Dickson DW, Davies P, Mayeux R, et al. Diffuse Lewy body disease: neuropathological and biochemical studies of six patients. Acta Neuropathologica 1987;75:8-15
24. Dickson DW. Dementia with Lewy bodies: neuropathology. J Geriatr Psychiatry Neurol 2002;15:210-216
25. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124
26. Prusiner S. Shattuck Lecture: neurodegenerative diseases and prions. N Engl J Med 2001;344:1516-1526
27. Collinge J. Molecular biology of prion disease. J Neurol Neurosurg Psychiatry 2005;76:906-919
28. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-1153
29. Knopman D, Boeve B, Petersen R. Essentials of the proper diagnosis of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc 2003;78:1290-1308
30. Korth C, May BC, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98:9836-9841
31. Ryou C, Legname G, Peretz D, et al. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest 2003;83:837-843
32. Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004;62:714-718
33. Anderson K. Huntington's disease and related disorders. Psychiatr Clin North Am 2005;28:275-290
34. Bonelli R, Wenning G, Kapfhammer H. Huntington's disease: present treatments and future therapeutic modalities. Int Clin Psychopharmacol 2004;19:51-62
35. Huntington's Disease Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003;61:1551-1556
36. Verhagen Metman L, Morris M, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002;59:694-699
37. Beister A, Kraus P, Kuhn W, et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl 2004;68:117-122
38. Huntington's Disease Study Group. Minocycline safety and tolerability in Huntington disease. Neurology 2004;63:547-549
39. Tabrizi S, Blarnire A, Manners D, et al. High-dose crealine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 2005;64:1655-1656
40. Josephs K, Holton J, Rossor M, et al. Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 2004;30:369-373
41. Mott R, Dickson D, Trojanowski J, et al. Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol 2005;64:420-428
42. Lipton A, White C, Bigio E. Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol (Berl) 2004;108:379-385
43. Knopman D, Mastri A, Frey W, et al. Dementia lacking distinctive histologic features. Neurology 1990;40:251-256
44. Knopman DS. Overview of dementia lacking distinctive histology: pathological designation of a progressive dementia. Dementia 1993;4:132-136
45. Skibinski G, Parkinson N, Brown J, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 2005;37:806-808
46. Boeve BF, Maraganore DM, Parisi JE, et al. Corticobasal degeneration and frontotemporal dementia presentations in a kindred with nonspecific histopathology. Dement Geriatr Cogn Disord 2002;13:80-90
47. Benson D, Davis R, Snyder B. Posterior cortical atrophy. Arch Neurol 1988;45:789-793
48. Caselli R, Jack C, Petersen R. Asymmetric cortical degeneration syndrome: clinical and radiologic correlations. Neurology 1992;42:1462-1468
49. Caselli R. Focal and asymmetric cortical degeneration syndromes. Neurologist 1995;1:1-19
50. Caselli R. Asymmetric cortical degeneration syndromes: clinicopathologic considerations. Mov Disord 1996;11:347-348
51. Petersen R, Smith G, Waring S, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neural 1999;56:303-308
52. Petersen R, Stevens J, Ganguli M, et al. Practice parameter early detection of dementia: mild cognitive impairment (an evidence-based review). Neurology 2001;56:1133-1142
53. Petersen R, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992
54. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-246
55. Jicha G, Parisi J, Dickson D, et al. Neuropathological outcome of mild cognitive impairment following progression to clinical dementia in a community-based cohort. Arch Neurol 2006;63:674-681
56. Petersen R, Parisi J, Dickson D, et al. Neuropathology of amnestic mild cognitive impairment. Arch Neurol 2006;63:665-672
57. Graham A, Davies R, Xuereb J, et al. Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain 2005;128:597-605
58. Petersen R, Thomas R, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388
59. McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58:1803-1809
60. Grossman M. Frontotemporal dementia: a review. J Int Neuropsychol Soc 2002;8:566-583
61. Neary D, Snowden J, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554
62. Miller BL, Chang L, Mena 1, et al. Progressive right frontotemporal degeneration: clinical, neuropsychological and SPECT characteristics. Dementia 1993;4:204-213
63. Miller BL, Darby A, Benson DF, et al. Aggressive, socially disruptive and antisocial behaviour associated with fronto-temporal dementia. Br J Psychiatry 1997;170:150-154
64. Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997;58:212-216
65. Moretti R, Torre P, Antonello R, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms: a randomized, controlled, open 14-month study. Eur Neurol 2003;49:13-19
66. Deakin J, Rahman S, Nestor P, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004;172:400-408
67. Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004;17:355-359
68. Moretti R, Torre P, Antonello R, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2004;21:931-937
69. Mesulam M. Primary progressive aphasia without generalized dementia. Ann Neurol 1982;11:592-598
70. Mesulam MM. Primary progressive aphasia. Ann Neurol 2001;49:425-432
71. Reed D, Johnson N, Thompson C, et al. A clinical trial of bromocriptine for treatment of primary progressive aphasia [letter]. Ann Neurol 2004;56:750
72. Kompoliti K, Goetz C, Boeve B, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998;55:957-961
73. Tang-Wai D, Graff-Radford N, Boeve B, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004;63:1168-1174
74. McKeith IG, Dickson DW, Lowe J. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872
75. Boeve B, Silber M, Ferman T, et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001;16:622-630
76. Boeve B, Silber M, Parisi J, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003;61:40-45
77. Boeve BF, Silber MH, Ferman TJ. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:146-157
78. Boeve B. Dementia with Lewy bodies. In: Petersen R, ed. Continuum. vol 10. Minneapolis. Minn: American Academy of Neurology; 2004:81-112
79. Thaisetthawatkul P, Boeve B, Benarroch E. et al. Autonomic dysfunction in dementia with Lewy bodies. Neurology 2004;62:1804-1809
80. Dickson DW, Crystal H, Mattiace LA, et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathologica 1989;78:572-584
81. Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006;63:197-202
82. Salmon D, Galasko D, Hansen L, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996;31:148-164
83. Ferman TJ, Boeve BF, Smith GE, et al. REM sleep behavior disorder and dementia: cognitive differences when compared with AD. Neurology 1999;52:951-957
84. Ferman TJ, Smith GE, Boeve BF, et al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease. Clin Neuropsychol 2006;20:623-636
85. Barber R, Ballard C, McKeith IG, et al. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000;54:1304-1309
86. Barber R, McKeith IG, Ballard C, et al. A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study. Dement Geriatr Cogn Disord 2001;12:198-205
87. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036
88. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurology. 2004;3:19-28
89. Aarsland D, Andersen K, Larsen J, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392
90. Apaydin H, Ahlskog J, Parisi J, et al. Parkinson's disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-112
91. Boeve BF, Silber MH, Ferman TJ. Current management of sleep disturbances in dementia. Curr Neurol Neurosci Rep 2002;2:169-177
92. Tariot P, Profenno L, Ismail M. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 2004;65(suppl 11):11-15
93. Sink K, Holden K, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608
94. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982;216:136-144
95. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916-919
96. Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442:920-924
97. Mackenzie IR, Baker M, West G, et al. A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17, pt 4. Brain 2006;129:853-867
98. Caselli RJ, Beach TG, Yaari R, et al. Alzheimer's disease a century later. J Clin Psychiatry 2006;67:1784-1800